Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sanofi is conducting a Phase 2 proof-of-concept study titled ‘A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)’. The study aims to evaluate the effectiveness, safety, and tolerability of lunsekimig as an add-on therapy for adults with CRSwNP who are not adequately managed with intranasal corticosteroids.
The intervention involves administering lunsekimig, a subcutaneous drug, every four weeks alongside intranasal mometasone furoate nasal spray. The study compares this treatment against a placebo to determine its efficacy in improving patient outcomes.
This interventional study is randomized with a parallel assignment model and quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are blinded. The primary goal is to treat CRSwNP effectively.
The study began on July 17, 2024, with an estimated primary completion date yet to be announced. The last update was submitted on June 25, 2025, indicating ongoing recruitment and progress.
The successful outcome of this study could positively influence Sanofi’s stock performance by demonstrating the potential of lunsekimig in treating CRSwNP, a condition with limited treatment options. This could enhance investor confidence and position Sanofi competitively within the pharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.